All companies
InVirtuoLabs logo🇨🇭

InVirtuoLabs

Swiss biotech startup that combines AI and molecular simulation to discover drugs faster.

StartupSeed🇨🇭 Lugano, Switzerland
2024Founded
11–50Team size
€2.85MRaised

About

InVirtuoLabs is a biotech startup founded in Lugano, Switzerland, in 2024. Its legal name is In Virtuo Laboratories SA. It combines machine learning, including generative chemistry, with physics-based molecular simulations to find and optimize drug candidates. The company runs its own drug discovery projects, offers its virtual laboratory platform, and co-develops drugs with pharmaceutical companies. It is supported by the USI Startup Centre incubation program.

Products & services2 products · 1 service

productLive since July 2025

InVirtuo Platform

End-to-end AI drug discovery platform that combines machine learning with physics-based molecular simulations.

+ What's included
For: Pharmaceutical and biotech companies
  • InVirtuoMOL: molecular machine learning engine that assesses the properties of drug candidates
  • InVirtuoGEN: multimodal generative AI for designing new molecules
  • InVirtuoSIM: physics-based simulations
service

Co-development with pharma

Joint R&D projects in which the platform is used to design and optimize drug candidates for a partner.

+ What's included
For: Pharmaceutical and biotech companies
  • Covers hit identification, lead optimization and ADMET prediction
productIn development

Proprietary drug discovery pipeline

In-house drug candidates for metabolic and neurological disorders.

+ What's included
  • Four internal candidates, IVL-001 to IVL-004
  • Stages listed range from hit discovery to preclinical validation

Customers

Pharmaceutical and biotech companies that work with InVirtuoLabs on co-development projects.

Traction

Updated Oct 2026
€2.3MEurostars grant for the NEUROSPARK project it leads
4in-house drug candidates in the pipeline
Billionsmolecules generated and evaluated daily by its chemical language model
36months planned for the NEUROSPARK project

Funding

€2.85Mraised across 1 round
Seed · 2025
€2.85M

Team1 on Openfor

Open topick one to start a conversation

Customers & pilots
Co-development with pharmaceutical companies is one of the three pillars of its business model, and it already works with several pharmaceutical and biotech firms on co-development projects.In the company's own words
Openfor.co network

Put your company on Openfor. Get found.

Show your products, customers and traction to founders, investors and partners across 30+ countries.